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Abstract: MDMA, amphetamine and 
methamphetamine are produced in the 
European Union in illicit laboratories to satisfy 
the demands of European consumers, and in 
the case of MDMA in particular, increasingly 
to supply consumers in other regions of the 
world. To produce these illicit drugs, chemical 
starting materials called drug precursors 
are needed. These chemicals may also have 
legitimate uses, necessitating a regime of 
regulation at the global level to prevent their 
diversion for illicit use and thereby limiting the 
supply of illicit drugs. A set of EU regulations 
provide an implementing framework for 
precursor trade within the European Union 
and between the European Union and the rest 
of the world.
In order to avoid regulatory regimes, 
producers of illicit synthetic drugs have 
introduced alternative chemicals that are 
not listed in the precursor regulations. These 
chemicals, which are normally imported, are 
converted into drug precursors that are then 
used for synthetic drug production. Because 
alternative chemicals are not controlled, 
they are cheaper than drug precursors and 
can be traded with little risk of interdiction 
or heavy penalties. The emergence of these 
new substances is a serious challenge to the 
international precursor control system.
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I  Introduction
The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) is involved in monitoring the illicit drug market in 
the European Union. When considering the illicit drug market 
a broad definition is used, encompassing the illicit production, 
trafficking, wholesale distribution and sale of illicit drugs to 
the end user. The drug market has wide-ranging impacts on 
both security and public health, and therefore such a holistic 
and systemic perspective is important for the effective delivery 
and monitoring of drug control policy and supply reduction 
activities. The availability of drug precursors has a direct impact 
on illicit drug production activities. 
Apart from drugs that are used in their natural form, such as 
cannabis, or medicines diverted from legitimate supplies, 
the production of illicit drugs requires the use of chemicals 
either to facilitate their extraction from natural materials, 
or to form semi- or fully synthetic substances. Restricting 
the availability of those chemicals, the drug precursors, has 
been a key component of drug supply reduction efforts since 
the late 1980s. At global level, the prevention of diversion of 
drug precursors, solvents and reagents used for illicit drug 
manufacture is underpinned by the United Nations Convention 
Against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 (‘the 1988 UN Convention’). Under the 
1988 UN Convention, the International Narcotics Control 
Board (INCB) has the responsibility to monitor Governments’ 
control over drug precursors used in the illicit manufacture 
of drugs, and to assist them in preventing the diversion of 
those chemicals into the illicit traffic. In the European Union, 
competent authorities, typically the customs, police or 
health authorities in each Member State, are responsible for 
implementing the EU regulations on drug precursors. These 
entities work in close cooperation with industry in order to 
implement the European drug precursor regulations. Both 
the UN Convention and EU regulations are based on lists of 
substances that are subject to a variety of controls.
To circumvent the precursor control system, producers of illicit 
synthetic drugs have sought alternative chemicals that are not 
listed as drug precursors. Once imported, these substances 
can be transformed into drug precursors relatively easily. These 
alternative substances have been called ‘pro-precursors’ 
(King, 2009) ‘pre-precursors’ (EMCDDA, 2009) or ‘masked 
precursors’ (INCB, 2019). The reduced risk of interception 
(at least initially), the ability to import them without fear of 
sanctions and the lower price of the unregulated chemicals 
make this an attractive proposition for drug producers (Tops et 
al., 2018).
I  Scope of this report
The chemicals used for the production of the main synthetic 
drugs produced in the European Union — amphetamine, 
methamphetamine and MDMA — are the focus of this 
paper. Historically, these drugs were produced by chemically 
modifying starting materials, referred to as drug precursors. 
The effective control of the trade in these starting materials 
under precursor legislation caused the manufacturers to 
seek alternative chemicals and synthesis pathways for the 
production of these drugs (see Figure 1). In the past 10 or so 
years, a number of approaches have been used to produce 
synthetic drugs in the absence of easily diverted precursors. 
One approach involves producing the precursor from a non-
controlled substance, for example BMK from APAA. Another 
approach relies on N-protected derivatives of drugs, non-
controlled substances that can be converted into illicit drugs. 
For the purpose of this paper, the term alternative chemicals 
covers the wide range of substances variously referred to in 
both official and unofficial reports as ‘designer precursor’, 
‘masked precursor’, ‘pre-precursor’ or ‘masked drug’. 
The next section explains how the precursors and alternative 
chemicals can either be ‘scheduled’ or ‘non-scheduled’, that 
is, included or not included in the lists contained in drug 
precursor regulations.
I  Regulation of drug precursors in the European Union
The European Union implements the 1988 UN Convention 
through two regulations of the European Parliament and 
of the Council. These are complemented with a number of 
Commission delegated and implementing regulations, which 
set out the provisions in detail. These regulations are directly 
applicable in the Member States. The delegated regulations 
may be amended after consulting the Group of Experts on 
Drug Precursors, which meets regularly and is composed of 
expert representatives from each EU Member State.
The regulations implement the 1988 UN Convention and are 
established to prevent the diversion of substances into illicit 
channels. This is an important point which will be further 
mentioned in the discussion.
Trade in drug precursors between the European Union and 
third countries is regulated through Regulation (EC) No 
111/2005, as amended by Regulation (EU) No 1259/2013 
(see consolidated version). The trade between EU Member 
States is regulated by Regulation (EC) No 273/2004, 
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amended by Regulation (EU) No 1258/2013 (see consolidated 
version). Each consolidated version contains an annex, 
listing the substances to which the regulations apply. 
European Commission delegated regulations place new 
substances under control measures by adding them directly 
to the regulations. Substances brought under control in this 
way include chloroephedrine and chloropseudoephedrine 
(precursors for methamphetamine) in 2016 and NPP and 
ANPP (precursors for fentanyl and derivatives) in 2018.
In addition, the regulations are supplemented by additional 
practical tools, such as ‘Guidelines for economic operators’ 
and e-learning courses for such operators and for customs 
authorities.
Key
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FIGURE 1
Synthetic drugs, precursors and related chemicals: understanding the connections
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These regulations set out the procedures, working arrangements 
and limits for economic operators trading in drug precursors. The 
provisions include rules for obtaining and checking licences and 
registrations, statutory reporting obligations, import and export 
procedures, and the identification of anomalies or irregularities 
(‘suspicious transactions’). 
Certain terms are defined in the EU regulations, including 
‘scheduled substance’ and ‘non-scheduled substance’. A 
scheduled substance is one that is contained in the annex of 
the regulations, including any mixtures or natural products 
(if the scheduled substance contained therein can be easily 
extracted), but excluding any medicinal products containing 
them (apart from those in category 4 of 111/2005). A non-
scheduled substance is any substance which, although 
not listed in the annex, is identified as having been used 
for the illicit manufacture of narcotic drugs or psychotropic 
substances. 
At international level, the 1988 UN Convention lists drug 
precursor chemicals in two tables. Table I contains substances 
which can be converted readily to controlled drugs or are 
essential for drug manufacturing, while Table II contains 
other chemicals such as solvents and reagents commonly 
used for drug processing. The substances listed in Table I are 
subject to more stringent controls than those in Table II. In 
the EU regulations, all of the chemicals in UN Tables I and II 
are broken down into four categories, described below. This 
four-tier categorisation system allows a greater flexibility in the 
application of controls, checks and monitoring, tailored to the 
needs of the European Union.
Category 1
This category contains the substances that are readily 
convertible to controlled drugs, and are subject to the strictest 
controls. Many of these are contained in Table I of the 1988 
UN Convention.
Substance UN 
Table
Typically used to 
make
1-Phenyl-2-propanone (BMK, P-2-P) I Amphetamine
3,4-Methylenedioxyphenylpro-
pan-2-one (PMK, MD-P-2-P)
I MDMA
4-Anilino-N-phenethylpiperidine 
(ANPP)
I Fentanyl derivatives
Alpha-phenylacetoacetonitrile 
(APAAN)
I Amphetamine
Chloroephedrine – Methamphetamine
Chloropseudoephedrine – Methamphetamine
Ephedrine I Methamphetamine
Ergometrine I LSD
Ergotamine I LSD
Substance UN 
Table
Typically used to 
make
Isosafrol (cis + trans) I MDMA
Lysergic acid I LSD
N-acetylanthranilic acid I Methaqualone
Norephedrine I Methamphetamine
N-phenethyl-4-piperidone (NPP) I Fentanyl derivatives
Piperonal I MDMA
Pseudoephedrine I Methamphetamine
Safrole I MDMA
The stereoisomeric forms of the substances listed in this category not being 
cathine (also known as (+)-norpseudoephedrine), whenever the existence of such 
forms is possible. The salts of the substances listed in this category whenever the 
existence of such salts is possible and not being the salts of cathine.
Category 2 
This category contains substances that are extensively 
used in the chemicals industry and which are also essential 
for drug processing (e.g. acetic anhydride and potassium 
permanganate for heroin and cocaine processing). These come 
from Table I or Table II of the 1988 Convention.
Substance UN 
Table
Typically used to 
produce
Acetic anhydride (a) I Heroin
Phenylacetic acid I Amphetamine
Anthranilic acid II Methaqualone
Piperidine II Phencyclidine
Potassium permanganate I Cocaine
The salts of the substances listed in this category whenever the existence of such 
salts is possible.  
(a) In Regulation No 273/2004 of the European Parliament and of the Council of 
11 February 2004 on drug precursors, Category 2 is split in two subcategories, with 
acetic anhydride appearing in Category 2A and the others listed in Category 2B.
Category 3 
This category contains the reagents and solvents typically used 
in drug processing found in Table II of the 1988 Convention. 
Substance UN Table Typical use
Hydrochloric acid II Reagent
Hydrogen chloride – Reagent
Sulfuric acid II Reagent
Toluene II Solvent
Ethyl ether II Solvent
Diethyl ether – Solvent
Acetone II Solvent
Methylethylketone II Solvent
The salts of the substances listed in this category whenever the existence of such 
salts is possible and not being the salts of hydrochloric acid and sulfuric acid.
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Category 4 (1)
This category relates specifically to medicinal products 
and veterinary medicinal products containing ephedrine, 
pseudoephedrine or their salts. 
Substance UN 
Table
Typically used to 
produce
Medicinal products and veterinary 
medicinal products containing 
ephedrine or its salts
– Methamphetamine
Medicinal products and veterinary 
medicinal products containing 
pseudoephedrine or its salts
– Methamphetamine
(1)  Category 4 only exists in Regulation 111/2005 relating to extra-EU trade.
All of the substances contained on the UN lists are present in 
the EU lists, however, some additional chemicals are regulated 
in the European Union — these are chemicals not present in 
the UN lists that have been used in illegal drug manufacture in 
the European Union. Beyond the scheduled substance lists, the 
INCB maintains a limited international special surveillance list of 
non-scheduled substances. In the European Union, a ‘voluntary 
monitoring list’ is maintained by the European Commission. If 
necessary, the competent authorities of the EU Member States 
and the Commission may propose additions to the voluntary 
monitoring list in order to facilitate the identification of diversion 
attempts and respond rapidly to new trends.
The responsibilities of economic operators trading in drug 
precursors are summarised in a table of the ‘Guidelines 
for operators’ (see Figure 2) produced by the European 
Commission. 
Economic operators play a key role in preventing the diversion 
of drug precursors and must facilitate the identification of 
suspicious transactions involving all scheduled substances; 
this is mandatory for categories 1 to 4, and voluntary and 
strongly recommended for non-scheduled substances. These 
provisions have proven to be effective in relation to scheduled 
substances, to the extent that the main substances used for 
making amphetamine and MDMA in the European Union (BMK 
and PMK) are rarely encountered. Voluntary cooperation offers 
the necessary flexibility to quickly respond to changing trends 
and patterns of diversion of drug precursors.
FIGURE 2
Obligations on economic operators in the European Union
Category 1 Category 2 Category 3 Category 4
Common 
obligations 
(external/intra EU 
trade)
Notify suspicious transactions or orders  
...to the competent authorities
Appoint a responsible officer  
...who ensures compliance with legislation
Secure premises 
...against theft
Obtain a licence Obtain registration Obtain registration  
...only in the case of export
External trade Report annually to the competent authorities  
...on exports, imports, intermediary activities
Report annually on exports
Document and label all transactions  
...and keep records for 3 years
Obtain an export authorisation ...Only for certain countries 
of destination
Obtain an export 
authorisation 
Obtain an import 
authorisation 
Intra EU trade Report annually to the competent authorities  
...on quantities used and supplied, and customers
...Only upon request
Document and label all transactions  
...and keep records for 3 years
Obtain a customer declaration  
…per substance, indicating its uses, and the name and 
address of the customer
Supply only to customers 
holding a licence
Category 2A: supply only 
to customers holding a 
registration
Source: European Commission
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I  International cooperation
Drug precursors are produced all over the world. It is therefore 
essential that efficient and effective international cooperation 
is implemented in order to prevent their diversion to countries 
where drugs are produced. 
International cooperation on precursors is facilitated by two 
main online tools developed by the INCB. The first, known as 
the Pre-Export Notification Online (‘PEN Online’) system, was 
launched in March 2006 to facilitate the exchange of pre-
export notifications by the country of export to the country of 
import. The second, launched in March 2012, is the Precursor 
Incident Communication System (PICS), which facilitates 
communication and information sharing on precursor incidents 
between national authorities in 110 countries. Around 35 000 
pre-export notifications and 200-300 precursor incidents are 
communicated via these systems each year (INCB, 2019). Pre-
export notifications may result in Member States preventing 
the supply of a chemical, if the competent authority in the 
receiving country is not convinced of the legitimacy of the 
order. This is known as a ‘stopped shipment’.
In addition to the international framework of cooperation 
enshrined in the 1988 UN Convention, the European Union has 
established closer cooperation with some third countries by 
concluding bilateral agreements to prevent drug precursors’ 
diversion through monitoring licit trade.
At present the European Union has agreements on 
‘cooperation regarding the control of precursors and chemical 
substances frequently used in the illicit manufacture of 
narcotic drugs and psychotropic substances’ with 11 countries: 
Bolivia, Chile, China, Colombia, Ecuador, Mexico, Peru, Russia, 
Turkey, the United States and Venezuela. 
Another avenue exists in Europe for technical cooperation on 
the topic of drug precursors. The Council of Europe’s Pompidou 
Group hosts a drug precursors network which meets on an 
annual basis. This network brings together experts from law 
enforcement, competent authorities, specialised magistrates 
and representatives of the European Chemical Industry 
Council.
I  Precursors for synthetic drugs produced in the European Union
The main synthetic drugs produced in the European Union — 
amphetamine, MDMA and methamphetamine — are produced 
from the scheduled precursors, BMK, PMK, ephedrine and 
pseudoephedrine. This section describes the alternative routes 
to these precursors that have been reported in the European 
Union.
I  Routes to BMK
The concept of using alternative chemicals to make scheduled 
drug precursors has been known for some time. In Poland, 
three clandestine facilities manufacturing BMK from 
phenylacetic acid for sale to amphetamine manufacturers 
were dismantled in the 2000s (Krawczyk et al., 2009). In the 
European Union, perhaps the first recorded example of an 
alternative chemical being used in an illicit laboratory was in 
the Netherlands in 2008, when the ‘bisulfite adduct’ of BMK 
was detected. Such was the importance of this finding that 
in its annual report on precursors of 2009, the INCB urged 
governments globally to exercise vigilance with regard to 
the possible ‘chemical masking’ of scheduled precursors for 
illicit purposes (INCB, 2009). Since then, the situation has 
been continuously evolving, with controls being introduced 
on new substances often followed by the emergence of 
alternative chemicals, presenting challenges for detection and 
identification and frustrating drug supply reduction efforts. 
Illicit laboratories converting APAAN into BMK were first 
detected in Europe in the 2009-11 period (Europol, 2011), with 
European seizures of APAAN amounting to well over 40 tonnes 
in 2013. APAAN was controlled in Europe in December 2013 
and seizures for the next year fell to 11 tonnes. APAAN was 
subsequently placed in Table I of the 1988 UN Convention, 
effective from 6 October 2014. The response to this control 
was the emergence of APAA, a substance chemically related to 
APAAN (see Figure 3), which was first detected in Europe at the 
end of 2012 and found in so-called ‘conversion labs’ (places 
where precursor manufacture takes place) in the Netherlands 
in 2016. In 2017, a further development, possibly pre-empting 
the control of APAA was the appearance of MAPA (Figure 3). 
Between 2017 and August 2019 more than 10 tonnes of 
MAPA have been seized globally, mainly in the Netherlands. 
In March 2019, the Commission on Narcotic Drugs (CND) 
decided to add APAA to Table I of the 1988 Convention. In the 
same way APAA replaced APAAN to a certain degree when it 
was controlled, it is possible that MAPA could become the next 
alternative chemical of choice for producing BMK in Europe 
(see Figure 3).
Whereas APAAN was rapidly brought under control in 
the European Union and then internationally, the glycidic 
derivatives of PMK and BMK, which emerged in 2010 and 2012 
respectively (INCB, 2013), have not yet been subject to control 
measures. They have been detected in illicit drug laboratories 
in the European Union since 2015. It is worth noting that the 
glycidic derivatives of BMK are less commonly encountered 
than the PMK equivalents, perhaps due to the availability of 
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APAAN, APAA and then MAPA (INCB, 2019). The scheduling of 
APAA in the European Union is expected in 2020.
I  Routes to PMK
MDMA, commonly known as ‘ecstasy’ when found in the form 
of tablets, is produced primarily from PMK, which itself can be 
produced from piperonal and safrole (and safrole-rich oils). 
The global licit trade in PMK is almost non-existent. Legitimate 
trade of piperonal is known to be significant, whereas the 
licit trade in safrole and safrole-rich oils is considerably more 
limited. Since the 2000s, these chemicals have mainly been 
imported from Asia.
Seizures of safrole and safrole-rich oils and of PMK decreased 
considerably between 2008 and 2012, a period that 
coincided with the reduced availability of MDMA in Europe. 
While seizures of these substances in recent years have 
been uncommon, they have not completely disappeared; for 
example, more than 4 tonnes of PMK and almost 3 000 litres of 
safrole were seized in the Netherlands in 2017.
As mentioned earlier, PMK may be produced from alternative 
chemicals, such as glycidic derivatives of PMK and their salts 
and esters. Seizures of these substances were first detected in 
Europe in 2010, and for the first time found in illicit synthetic 
drug production laboratories in the Netherlands in 2015, 
perhaps as a result of the poor availability of safrole in the 
preceding years. 
In 2014, during a survey by the INCB on the use of alternative 
chemicals, several governments mentioned a substance called 
‘helional’ (2-methyl-3-(3,4-methylenedioxyphenyl)propanal), a 
precursor of MDMA and other similar substances. In May 2014, 
Dutch authorities reported a seizure of 800 litres of helional at 
a ‘clandestine warehouse’; more than 500 kilograms of APAAN 
was also seized from the same site (INCB, 2015), indicating 
that precursor developments continued to evolve and careful 
and continuous monitoring was essential. 
Seizure data confirm that, as noted above, the glycidic 
derivatives of PMK are the most common alternative 
substances used to produce PMK in the European Union. 
In 2017, a seizure of ‘3,4-methylenedioxyphenylacetonitrile’ 
was made in France. This substance is to PMK what APAAN 
is to BMK, clearly demonstrating the interplay between the 
alternative chemicals used to produce drug precursors for illicit 
drug manufacture.
The CND decided in March 2019 to add glycidic derivatives of 
PMK to Table I of the 1988 Convention (at the same time as 
the decision to control APAA).
I  Routes to ephedrine
Ephedrine and pseudoephedrine and are internationally 
controlled drug precursors. They are the main precursors used 
for production of methamphetamine in Czechia, Bulgaria, 
Germany, Poland and Slovakia. Production based on ephedrine 
and pseudoephedrine results in d-methamphetamine 
(‘crystal meth’ or ‘ice’). Ephedrine and pseudoephedrine 
can be extracted from medicines, and some EU Member 
States such as the Czechia, and more recently Germany 
and Poland, have implemented national restrictions on the 
sale of such medicines. In these Member States, sales are 
restricted to small packet sizes sold under the supervision 
of a pharmacist. However, there is no harmonised approach 
to this at EU level, and the sale of medicines containing 
ephedrine or pseudoephedrine is not restricted in all Member 
FIGURE 3
Incidents involving APAAN, APAA and MAPA reported 
to INCB, 2012-18
Source: INCB (2019)
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States. This has given rise to the trafficking of such medicines 
from outside the European Union or from EU Member States 
with less restrictive sales regimes to Member States where 
methamphetamine production takes place.
In an apparently isolated case in Czechia in 2014, ephedrine 
was found to be produced via a novel method using l-PAC, 
which can be synthesised relatively easily from a specially 
modified yeast, dextrose and benzaldehyde.
Chloroephedrine is also a precursor for the production of 
d-methamphetamine. Multi-tonne quantities of this precursor 
were discovered during law enforcement operations in Czechia 
and Germany, also in 2014. Chloroephedrine is a chemical 
intermediate, produced as part of the methamphetamine 
synthesis process and has no licit use. Since July 2016, both 
chloroephedrine and chloropseudoephedrine have been 
scheduled as drug precursors in the European Union. 
The alternative chemicals used to produce ephedrine do not 
seem to have gained traction in methamphetamine production 
in Europe, perhaps due to the availability of alternative 
substances or the rapid response from the regulatory system. 
However, these developments strongly suggest that illicit 
synthetic drug producers perform their own research and 
development activities in order to keep ahead of the regulations.
I  ‘Precursor-free’ route
A recent and significant drug precursor development in the 
European Union is the use of non-scheduled substances 
that can be converted into illicit drugs without the need to 
involve the typical drug precursor at all. These are created 
by producing the drug and then making a derivative that is 
easily converted back to the drug. The number of these cases 
detected and reported to date has been low. Their existence, 
however, points to a concerning new and potentially important 
development in the precursor field. Although technically 
these substances may be considered as precursors, they 
are fundamentally different from all other precursors as they 
contain the full illicit drug molecule with a chemical group 
attached, rendering it a different chemical entity and therefore 
outside the international control regimes for illicit drugs 
and drug precursors. This is another example of innovative 
chemical development by illicit drug producers, using what 
are known in organic chemistry as protection/de-protection 
techniques. Using these techniques minimises the risks 
associated with the international trafficking of illicit drugs and 
drug precursors. 
This method was first documented in Europe in December 
2016, when N-t-BOC-MDMA and N-methoxycarbonyl-MDA 
were detected in the Netherlands. Using a rudimentary 
process of heating in acidic conditions for a relatively short 
time, these substances are readily converted to the illicit 
drugs MDMA and MDA respectively. According to the INCB, 
the first detection of N-t-BOC-MDMA was in Australia in 2015. 
The corresponding methamphetamine derivative, N-t-BOC-
methamphetamine was subsequently identified in China in 
2015 and in New Zealand in January 2017, where it was found 
in a consignment imported from China (INCB, 2018). N-t-BOC-
methamphetamine has not been detected in Europe (as of 
August 2019).
Such is the pace of change in this area that by the time this 
report is published, there may already be further developments 
and even more alternative substances and chemical 
innovations. There are several obvious alternative substances 
that could emerge in the near future, but these will not be 
speculated on here. Suffice to say, the EU retail synthetic drugs 
market is valued at more than EUR 1.5 billion (EMCDDA and 
Europol, 2019), and those involved in this trade are unlikely to 
stop their operations any time soon.
I  Discussion
The enhanced level of information exchange and international 
cooperation arising from the introduction of PEN Online and 
PICS has been central to improving precursor diversion control 
globally. Particularly in relation to BMK and PMK, the drug 
precursor regulations have been effective at what they were 
designed to do: prevent diversion from legal to illegal channels. 
In the past, a reduction in the availability of a particular 
precursor was sufficient to have an impact on the production 
of an illicit drug. An example of this is the significant reduction 
in the supply of MDMA at the end of the last decade, which 
coincided with a reduction in the availability of PMK and 
safrole around 2008 due to global precursor restriction efforts. 
Despite the success of this supply reduction effort, however, 
there were some unintended consequences: new psychoactive 
substances like m-CPP, BZP and to a lesser extent 
mephedrone replaced MDMA in a proportion of ecstasy tablets 
seized in the Netherlands during the same period (Figure 4). 
As with any manufacturing industry, ensuring the availability 
of the raw materials needed in the illicit sector is key to 
business continuity. The strategy adopted by synthetic 
drug manufacturers to achieve this has been to introduce 
alternative chemicals that can be readily transformed into 
the scheduled substances needed to produce illicit drugs. A 
prominent example of this was the erratic availability of BMK in 
Europe between 2006 and 2009, which led to the introduction 
of APAAN (see below). Such innovation in production methods 
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introduces new levels of complexity into this sector of the 
drugs market. Moreover, since non-scheduled chemicals are 
less risky to traffic, they are cheaper, too. According to the 
Dutch Police, in 2017 the black-market price of a litre of good 
quality BMK from China was more than EUR 1 000, while with 
the price of a kilogram of APAAN from China was EUR 35-50. 
Each kilogram of APAAN yields approximately 350 millilitres 
of BMK, which meant that the effective cost of APAAN was 
around one tenth that of BMK.
A key factor that characterises the recent changes is that the 
alternative chemicals entering the market differ fundamentally 
from substances like BMK and PMK, which were diverted 
from licit trade. The new ‘designer precursors’ have no known 
legitimate uses and are made specifically to circumvent 
controls, often being produced by rogue companies. As 
such, most of the tools available under the current legal 
framework, such as the notification requirement for suspicious 
transactions and import/export authorisations, which are 
designed to prevent such diversion from licit supply, are not 
effective to counter the use of alternative chemicals in illicit 
drug manufacture.
Another negative consequence of the introduction of 
alternative chemicals to make scheduled drug precursors has 
been the additional levels of processing that must go on in the 
illicit drug production laboratories or in dedicated ‘conversion 
labs’. This additional processing stage requires large amounts 
of additional chemical reagents and leads to the production 
of acidic waste, which is illegally dumped, entailing significant 
clean-up costs for authorities and land owners as well as 
causing damage to the environment (Claessens et al., 2019). 
This is particularly evident in the main synthetic drug producing 
region of Europe in the Netherlands and Belgium.
On the one hand, it can be argued that the effectiveness of 
controls has been so profound that scheduled drug precursors 
have to a large extent been replaced by alternative chemicals 
for synthetic drug production, at least for the main illicit 
synthetic drugs produced in Europe. On the other hand, the 
prevention of diversion of drug precursors has the goal of 
reducing the availability of the illicit drugs and with synthetic 
drug production in Europe currently at a high level, it appears 
that the international drug precursor control regime is 
challenged by these developments. The ability of organised 
crime groups to introduce cheaper, non-scheduled alternative 
chemicals means that the current system of maintaining a list 
appears not to be sufficient to reduce the supply of illicit drugs. 
Recognising this issue, the European Union introduced two 
innovative changes in the EU precursor legislation, known as 
the ‘catch all’ provision and the ‘fast-track’ procedure. 
The ‘catch-all’ provision, introduced at the end of 2013, allows 
Member States to prohibit the introduction of non-scheduled 
substances into the customs territory of the Union or their 
departure from it, where there is sufficient evidence that those 
substances are intended for the manufacture of illicit drugs. 
However, some Member States have reported some issues 
with its implementation.
The ‘fast track’ procedure was introduced at the same time and 
empowers the European Commission to add non-scheduled 
substance to the lists of scheduled substances by means 
of delegated acts. This is done when it is considered that 
voluntary monitoring by the industry is insufficient to prevent 
the use of a non-scheduled substance for the manufacture of 
illicit drugs. The ‘fast track’ procedure was used in the case of 
chloroephedrine and chloropseudoephedrine in July 2016, and 
NPP and ANPP (precursors used in the production of fentanyl 
and some of its derivatives) in February 2018.
At the time of writing this report, the European Commission is 
undertaking an evaluation of the precursor regulation regime in 
the European Union. 
I  Conclusion
The effective implementation of drug precursor legislation in 
the European Union has driven innovation in the precursor 
trade, as avoiding controls is an important factor for producers 
and importers of these substances. Another important factor 
that may have contributed to the successful prevention of 
diversion of scheduled drug precursors, and hence driven 
innovation, has been the introduction of the improved online 
FIGURE 4
Effects of restricted precursor availability on the content 
of ecstasy tablets in the Netherlands 
Source: Netherlands Forensic Institute
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tools, PEN Online and PICS. While authorities have become 
more connected, producers have reacted by circumventing the 
control regime, usually by research and development and often 
basic chemistry. 
There is no indication that such developments will diminish 
in the coming years. In fact, the precursor arms race between 
regulators and illicit drug producers can only be expected to 
intensify as the system adapts and reacts to the emergence of 
new alternative substances. The current approach is constantly 
being challenged by this phenomenon, and a fundamental 
discussion on drug precursor control has started at EU and at 
global level. Fresh ideas about how to counter these issues are 
needed if synthetic drug production in the European Union and 
the rest of the world is to be addressed. As noted in this paper, 
the European Union is already taking proactive measures 
to address these issues and, furthermore, stands ready to 
contribute to international efforts to find a way forward.
I  Abbreviations of chemical names
ANPP 4-anilino-N-phenethylpiperidine
APAA alpha-phenylacetoacetamide 
APAAN alpha-phenylacetoacetonitrile
BZP benzylpiperazine
l-PAC l-phenylacetocarbinol
m-CPP meta-chlorophenylpiperazine
MAPA methyl alpha-phenylacetoacetate
MDA 3,4-methylenedioxyamphetamine
MDMA 3,4-methylenedioxy-N-methylamphetamine
NPP N-phenethyl-4-piperidone 
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